“…4 Remission induction is a major block of chemotherapy, and several complications are known to occur during this phase—febrile neutropenia, sepsis, bleeding, anemia, gastrointestinal disturbances, hepatic dysfunction, pancreatitis, venous thrombosis, etc. 5 Hepatic dysfunction could be due to leukemic infiltrates in the liver, nonalcoholic steatohepatitis, sepsis, hepatotropic viral infections, therapy-related toxicity seen due to asparaginase, rarely hyperinflammatory syndromes like hemophagocytic lymphohistiocytosis (HLH), and indirect hyperbilirubinemia due to underlying genetic syndromes like Gilbert's syndrome. 6 Hepatic dysfunction can contribute to morbidity by adding on to the underlying disease, delaying chemotherapy, dose modifications of chemotherapeutic agents, and rarely can cause mortality due to fulminant hepatic failure.…”